ClinicalTrials.gg
CompletedNCT06778967Optimum 2Updated Nov 10, 2026

A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus

A Phase 3 interventional study of GZR18 and semaglutide in Type 2 Diabetes Mellitus (T2DM), sponsored by Gan & Lee Pharmaceuticals.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Gan & Lee Pharmaceuticals. · Phase 3, Interventional, and Treatment

Updated Nov 10, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,133
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 — 2 open to participants now, 5 under way, 1 of them phase 3. bofanglutide · Diabetes Mellitus, Type 2.

Enrollment
Largest of 10
1,133 · median 91
Started
2025
with 2 others
Phase 3
3 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
3 of 10
Gan & Lee Pharmaceuticals.

Among the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 3 that started in 2025, is one of 3 in phase 3, and was the 7th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 10 studies testing bofanglutide in Diabetes Mellitus, Type 2 are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About bofanglutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bofanglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The main purpose of this study is to investigate the Efficacy and Safety of GZR18 Injection in Chinese Subjects with Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Metformin Monotherapy or in Combination with Sodium-dependent Glucose Transporter 2 (SGLT2) Inhibitors or Sulfonylureas

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • T2DM is diagnosed for at least 12 weeks according to the diagnostic criteria of diabetes mellitus issued by the World Health Organization (WHO) in 1999 and the supplementary diagnostic criteria of WHO in 2011 ( diagnosis is recommended).
  • Antidiabetic drugs that meet any of the following within 8 weeks before screening:

    • A stable dose of metformin hydrochloride monotherapy at a dose of ≥ 1500 mg/day or the maximum tolerated dose ;

      • A stable dose of metformin (≥ 1500 mg/day or the maximum tolerated dose ) in combination with SGLT2 inhibitors;

        • A stable dose of metformin (≥1500 mg/day or a maximum tolerated dose \< 1500 but ≥ 1000 mg/day) in combination with a stable daily dose of sulfonylureas.
  • HbA1c ≥ 7.5% and ≤ 11% at screening (central laboratory).
  • BG \< 15 mmol/L at screening (central laboratory).

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus or special type of diabetes mellitus.
  • Diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar state within 6 months before screening, or diabetic ketosis at screening/before randomization.
  • Severe chronic complications of diabetes (such as proliferative retinopathy or maculopathy, diabetic painful neuropathy, intermittent claudication, or diabetic foot) at screening or before randomization.
  • History of acute or chronic pancreatitis and pancreatic injury before screening.
  • History or relevant family history of medullary thyroid cancer, multiple endocrine neoplasia (MEN) 2A or 2B before screening.
  • Any laboratory test indicator meeting the following criteria at screening or before randomization:
  • Calcitonin level ≥ 50 ng/L (pg/mL) at screening.
  • ≥ 3.0 × (ULN) or AST ≥ 3.0 × ULN or total ≥ 2.0 × ULN.
  • Estimated (eGFR) \< 60 mL/min/1.73 m2, calculated using CKD-EPI equation (see Appendix 3).
  • Fasting triglyceride (TG) ≥ 5.7 mmol/L or 500 mg/dL.
  • Blood amylase or lipase > 1.5 × ULN.
  • ≤ 100 g/L for women and ≤ 110 g/L for men.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,133 participants (actual)

Study arms

  • Experimental
    GZR18 Dose 1

    Participants will receive GZR18 subcutaneously (SC).

    Drug: GZR18

  • Experimental
    GZR18 Dose 2

    Participants will receive GZR18 subcutaneously (SC).

    Drug: GZR18

  • Active comparator
    semaglutide

    Participants will receive semaglutide subcutaneously (SC).

    Drug: semaglutide

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c)(%)

    Time frame: Baseline, Week 44

Secondary outcomes

  1. Change from baseline in mean 7-point self-measured blood glucose (SMBG)

    Time frame: week 44

  2. Proportion of subjects with salvage therapy.

    Time frame: week 44

  3. Change from baseline in weight (kg)

    Time frame: week 44

  4. Percent change in weight from baseline (%)

    Time frame: week 44

  5. Proportion of subjects with ≥ 5% and 10% decrease in weight from baseline.

    Time frame: week 44

  6. Treatment emergent adverse events (TEAEs)

    Time frame: week 44

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Sep 2026, 19 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2025
First posted
Jan 16, 2025
StartActual
Feb 13, 2025
Primary completionActual
Sep 18, 2026was Dec 2026
CompletionActual
Sep 18, 2026was Dec 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Primary completion
Dec 11, 2026→Sep 18, 2026 (actual)
Nov 10, 2026
Study completion
Dec 11, 2026→Sep 18, 2026 (actual)
Nov 10, 2026
Enrollment
1100 (estimated)→1133 (actual)
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Primary completion Dec 11, 2026→Sep 18, 2026 (now actual)
    Study completion Dec 11, 2026→Sep 18, 2026 (now actual)
    Enrollment 1100 (estimated)→1133 (actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06778967
Responsible party
Sponsor
First posted
Jan 16, 2025
Start date
Feb 13, 2025
Primary completion
Sep 18, 2026
Completion
Sep 18, 2026
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bofanglutide

Start the discussion